Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase III clinical trials on FXS6837 capsules (original project code: XH-S003, hereinafter referred to as “FXS6837”) for the treatment of paroxysmal nocturnal hemoglobinuria in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.